Today: 8 June 2026
Browse Category

Biotechnology 11 May 2026 - 4 June 2026

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
4 June 2026
·······
Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech jumps 42% as traders look at results from small cancer study

Legend Biotech shares soared 42% to $36.28 after early Phase 1 data showed all six higher-dose patients with relapsed or refractory B-cell non-Hodgkin lymphoma responded to its in vivo CAR-T therapy LB2501, with five complete responses; UBS raised its price target to $49, citing the therapy’s outlook, but the results are early and based on a small group with short follow-up.
3 June 2026
···
Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax shares plunged 33.7% to $86.01 after hours on Nasdaq despite its ulcerative colitis drug obefazimod hitting the main goal in a 44-week Phase 3 trial. Both 25 mg and 50 mg doses showed over 50% clinical remission versus 10.4% for placebo. No new safety signals reported. Abivax plans a U.S. FDA filing late Q4 2026. Cash reserves stood at €491.6 million at March-end, funding into Q4 2027.
2 June 2026
···
Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines shares rose 1.9% premarket to $157.48 after Phase 3 trial data showed its experimental pill daraxonrasib nearly doubled median survival in pancreatic cancer to 13.2 months vs. 6.7 for chemo. The company, with no approved drugs or revenue, plans to file for FDA approval using a priority voucher. High-grade side effects were less common than chemo. Market cap stood at $31.2 billion.
1 June 2026
···
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
20 May 2026
···
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
20 May 2026
·
Silexion’s Cancer Trial Push Puts Focus on Cash

Silexion’s Cancer Trial Push Puts Focus on Cash

Silexion reported Israeli clearance and a German filing for its SIL204 pancreatic cancer drug, keeping its Phase 2/3 trial on track for a second-quarter start. The company posted a first-quarter net loss of $2.7 million and held $2.4 million in cash at March 31. Shares closed at 26.9 cents Tuesday after a sharp drop last week. Management warned of “substantial doubt” about ongoing operations without new funding.
20 May 2026
··
Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics Jumps; $3 Million Deal Looms

Co-Diagnostics announced a $3 million private placement after its stock surged 43.8% Tuesday, then fell 13.3% in after-hours trading. The company will sell 1.65 million shares or pre-funded warrants, plus warrants for up to 3.29 million more shares, nearly doubling its share count. The move follows its completion of a Bundibugyo virus assay as Ebola spreads in Congo and Uganda. Co-Diagnostics reported $8.2 million in cash at March 31.
20 May 2026
··
Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics shares surged 51% Tuesday after the company announced completion of an assay strategy for the Bundibugyo Ebola virus, though the test is not yet for sale and awaits regulatory approval. Trading volume topped 94 million shares. The company reported $8.23 million in cash at March 31 and a quarterly net loss of $9.14 million, raising concerns about its financial stability.
19 May 2026
···
Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharma Stock Gains After Antibody News, 2027 Lyme Trial Planned

Tonix Pharmaceuticals filed new Phase 1 modeling data showing its experimental Lyme disease antibody, TNX-4800, could maintain serum levels above a proposed protective threshold for six months with a two-dose regimen. Shares rose $1.65 to $15.74 Friday. The company plans a Phase 2 trial in 2027, pending FDA agreement. No Lyme vaccine is currently available in the U.S.
15 May 2026
···
REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
14 May 2026
····
WORK Medical Technology Group Stock Triples After AI BioToken Deal — What Investors Need to Know

WORK Medical Technology Group Stock Triples After AI BioToken Deal — What Investors Need to Know

WORK Medical Technology Group’s Nasdaq-listed shares surged 206% Monday to $3.92 after announcing an AI partnership with Shanghai Novabioplus Biotechnology. The stock swung between $0.19 and $4.09 before falling 48% in early Tuesday premarket. The companies plan to develop AI-driven models for protein and biological data but disclosed no financial terms or customer details.
12 May 2026
···
Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna’s early-stage hantavirus vaccine research drew renewed attention after a deadly Andes virus outbreak on the MV Hondius cruise ship, with six confirmed cases and three deaths reported. Moderna shares closed up nearly 12% Friday. WHO and ECDC rated the broader public risk as low, but recommended a 42-day quarantine for passengers. No approved vaccine or treatment for Andes virus exists, according to the CDC.
11 May 2026
··
1 2 3 … 18

Stock Market Today

  • Bitcoin Poised for Rally if Nasdaq Continues to Decline
    June 7, 2026, 10:08 PM EDT. Bitcoin (BTC) held crucial support above $60,000 over the weekend, rising 6.5% from a low near $59,100 to about $62,950. Analysts highlight BTC's position above the 200-week simple moving average (SMA) near $61,880, a key long-term support that has historically marked market bottoms. Meanwhile, the Nasdaq Composite plunged over 4% on Friday, its steepest drop since April 2025, and technical indicators suggest a potential further decline of more than 10% toward its 20-week SMA near 22,905 points. This divergence has led to Bitcoin becoming historically undervalued relative to Nasdaq, with the BTC-Nasdaq relative strength index (RSI) reaching an oversold level last seen before a 30% BTC rally. If Bitcoin maintains support, it could rally toward the 50-week SMA near $92,630, benefiting from Nasdaq's underperformance.

Latest articles

Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

8 June 2026
Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

8 June 2026
NIO’s U.S.-listed shares plunged 5.8% Friday, erasing a delivery-led rally, as investors focus on whether June sales can hit the company’s Q2 target after May deliveries rose 62.3% to 37,705. NIO needs 42,939–47,939 June deliveries to meet guidance, with risks from China’s saturated car market and recent price pressure.
HPE Stock Faces AI Rally Test With Monday In Focus

HPE Stock Faces AI Rally Test With Monday In Focus

8 June 2026
Hewlett Packard Enterprise plunged 8.36% Friday to $49.20, capping a three-day slide and erasing gains after a post-earnings surge, even as it raised its fiscal 2026 revenue growth outlook to 29%-33% and boosted non-GAAP EPS guidance, with analysts warning that rapid gains may have priced in too much hope too quickly.
Go toTop